logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Metastatic HR+ breast cancer: subgroup OS benefit with CDK4/6 inhibitors plus ET

Meta-analysis examines 6 phase 2/3 RCTs.